Truveta Tru enables researchers to accelerate their medical research
Truveta Studio now includes Truveta Tru, a research assistant powered by generative AI
October 29, 2024 09:18 ET | Truveta
BELLEVUE, Wash., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Today, Truveta announced its latest AI innovation – Truveta Tru, Truveta Studio’s research assistant powered by generative AI. Trained on the...
The University of Washington's CHOICE Institute partners with Truveta to advance health economics and outcomes research
The CHOICE Institute partners with Truveta to advance health economics and outcomes research
September 04, 2024 09:00 ET | Truveta
BELLEVUE and SEATTLE, Wash., Sept. 04, 2024 (GLOBE NEWSWIRE) -- The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington’s School of Pharmacy has...
Truveta Research study published in JAMA Internal Medicine compares tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss
Truveta’s real-world data study comparing tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss published in JAMA Internal Medicine
July 08, 2024 11:16 ET | Truveta
BELLEVUE, Wash., July 08, 2024 (GLOBE NEWSWIRE) -- Today Truveta announced that its comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide...
Truveta welcomes Rod Hochman, MD, president and CEO, Providence, as its new Board of Directors Chair
Truveta welcomes Rod Hochman, MD, president and CEO of Providence, as new Truveta Board of Directors Chair
May 13, 2024 09:00 ET | Truveta
BELLEVUE, Wash., May 13, 2024 (GLOBE NEWSWIRE) -- Today Truveta, a growing collective of more than 30 health systems with a mission of Saving Lives with Data, welcomes Rod Hochman, MD, president and...
Truveta now empowers researchers to learn from millions of de-identified medical images – across all modalities, including MRI, CT, X-ray, ultrasound, mammogram, and nuclear medicine – integrated with the patient’s EHR data.
Using clinical-led AI, Truveta expands clinical notes and medical images available to advance research
May 02, 2024 09:00 ET | Truveta
BELLEVUE, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Today Truveta announced the availability of expanded concepts from clinical notes -- including family history, medication details reported to...
Exploring a mother-child patient population for which mothers received a flu vaccine during pregnancy to understand virus protection for the child after birth using Truveta Studio
Truveta delivers largest and most complete mother and child EHR dataset to advance healthcare
April 25, 2024 09:00 ET | Truveta
BELLEVUE, Wash., April 25, 2024 (GLOBE NEWSWIRE) -- Truveta, the company with a mission of Saving Lives with Data, announced today the largest and most complete mother-child electronic health record...
Truveta Research on
Truveta Research on increased speech delays in children during the pandemic published in JAMA Pediatrics
December 05, 2023 09:00 ET | Truveta
BELLEVUE, Wash., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Today Truveta announced new research published in JAMA Pediatrics exploring the incidence of first-time speech delays in children under the age of...
Truveta is a growing collective of health systems that provide more than 18% of all daily clinical care in the US.
Truveta welcomes Patrick Caubel, Pfizer Chief Safety Officer, to its Board of Directors
December 04, 2023 09:00 ET | Truveta
BELLEVUE, Wash., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Truveta, the company with a mission of saving lives with data, welcomes its first member from the life science industry to its Board of Directors....
Truveta Research found that patients with overweight or obesity taking tirzepatide (Mounjaro) experienced a greater percentage change in body weight than those taking semaglutide (Ozempic) for weight loss.
Largest real-world study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss
November 27, 2023 09:00 ET | Truveta
BELLEVUE, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Today Truveta announced new comparative effectiveness research exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide...
One of 2.7 million redacted echocardiogram reports available for study in Truveta.
Truveta announces availability of millions of echocardiogram reports to advance cardiovascular research
November 08, 2023 09:00 ET | Truveta
BELLEVUE, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Today Truveta announced the availability of more than 56.6 million clinical observations from more than 2.7 million echocardiogram reports from...
Next Page keyboard_arrow_right